I-MAK

FTC building

Pharma

FTC takes aim at 'sham' biopharma patents

The FTC has warned pharma companies that they could face legal action by making “improper” listings in the FDA’s Orange Book, a registry of patents.

Kevin Dunleavy Sep 14, 2023 3:55pm

FDA Building 2

Senate, FDA urge USPTO to alter drug patent application process

Sep 14, 2021 9:15am